ARCHIVES

FDA Spells Out Requirement For INDs For Cancer Drugs.

This article is from The Cancer Letter archive.

Vol. 28 No. 20 | May 17, 2002

Download PDF Visit The Full Archive

Related Articles

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012

In Brief: Clearinghouse Charter Renewed For Two Years; Good On China, Carbone On Communciation

May 26, 1978

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004

Committee Holds Up RFP For Frederick, Asks Six Month Delay

September 24, 1976

Firm Reports Limited Market For Self-Test Detection Methods

July 29, 1983

New Drug Combination Improves Survival Of Ewing’s Sarcoma, Pediatric Study Finds

February 28, 2003